Researchers have developed a novel CRISPR-Cas9 delivery system utilising cryo-shocked lung tumour cells to target non-small cell lung cancer (NSCLC), particularly those with KRAS mutations. The technique involves using lung tumour cells treated with rapid liquid nitrogen shock, effectively inactivating their pathogenicity while preserving their structure and surface receptors. These cryo-shocked cells serve as carriers for CRISPR-Cas9, aimed at editing the CDK4 gene - a key player in the proliferation of KRAS-mutant NSCLC cells.
A novel method for precise gene editing in adult organs utilises in vivo cleavable donor plasmids for CRISPR-Cas9 and CRISPR-Cas12a. The method employs hydrodynamic delivery of targeting plasmids, showcasing a substantial improvement over traditional techniques and significantly enhancing gene editing efficiency in adult mouse livers. The research conducted precise in-frame knock-ins using both CRISPR-Cas9 and Cas12a systems, successfully integrating reporter gene cassettes into targeted genomic loci in the liver of adult mice.
CRISPR-Cas9 Gene Editing: Curing Genetic Diseases by Inherited Epigenetic Modifications. This review critically evaluates CRISPR-Cas9's potential in treating genetic diseases, focusing on therapeutic applications, challenges, and future directions while emphasising the importance of informed use among medical professionals to maximise its benefits and mitigate risks.
Advances and Challenges of Sensing in Water Using CRISPR-Cas Technology. This review delves into the prospective use of CRISPR-Cas technology for sensing in water, exploring its capabilities in detecting diverse biomarkers, hazardous substances, and varied reactions in water and wastewater systems.